Every development that changes what you can legally buy or what it costs, newest first, each with its primary source, a confidence label and what it means for cash-pay patients. Updated October 15, 2026.
As of October 15, 2026, compounded tirzepatide and semaglutide are not FDA-approved and may be compounded only for an individual patient with a documented clinical difference; FDA’s proposal to keep them off the 503B bulks list has no final decision; retatrutide and cagrilintide cannot be compounded; and a peptide interim access policy is under White House review.
Qualification: items marked “reported” rest on press accounts we could not confirm on a government page.
CNN published an investigation into telehealth GLP-1 prescribing to people with anorexia and other eating disorders.
What it means for cash-pay patients: A legitimate program screens for eating disorders before prescribing; an intake that never asks is a warning sign.
Source: CNN · Confidence: confirmed · read October 15, 2026
The OIRA review list on reginfo.gov shows "Interim Access Policy for Compounding Using Certain Peptides" (HHS/FDA, RIN 0910-ZD94, stage Notice) received October 14, 2026 and pending review; no text is posted. Reuters reported the filing on October 15. The AP, citing two people, said the policy would let pharmacies make some popular peptides, including BPC-157. A Washington Post report on October 7 had described a temporary plan while new rules are written.
What it means for cash-pay patients: Nothing has changed yet. Until a policy is published, BPC-157 and similar peptides remain outside FDA’s compounding categories.
Source: OIRA, reginfo.gov · Reuters via Yahoo News · Washington Post via Anchorage Daily News, Oct 7 · Confidence: confirmed (filing); reported (content) · read October 15, 2026
CNBC reported Walmart’s 2027 benefits: Ozempic and Mounjaro at no cost for employees with type 2 diabetes. GLP-1s prescribed for weight loss are still not covered.
What it means for cash-pay patients: Employer coverage is moving for diabetes, not for weight loss; cash-pay remains the route for most weight-loss patients.
Source: CNBC · Confidence: confirmed · read October 15, 2026
Ozari Health announced two plans, including "Ozari One" at $125 a month for tirzepatide and $86 for semaglutide at every dose.
What it means for cash-pay patients: This is a press announcement. Ozari is not in our price index until we can read the price on its own checkout pages.
Source: Yahoo Finance (press coverage) · Confidence: reported · read October 15, 2026
FDA’s "Concerns with unapproved GLP-1 drugs used for weight loss" page (current as of October 1, 2026) states that retatrutide and cagrilintide cannot be used in compounding under federal law and that multi-dose compounded GLP-1 vials should be discarded 28 days after first use.
What it means for cash-pay patients: Any "retatrutide" offered online is an unapproved drug. If you use a compounded multi-dose vial, date it when you first puncture it.
Source: U.S. FDA · Confidence: confirmed · read October 15, 2026
Rhode Island Medicaid plans stopped covering GLP-1s prescribed solely for weight loss from October 1, 2026, according to a plan notice to providers.
What it means for cash-pay patients: Rhode Island Medicaid members using a GLP-1 for weight loss need a cash-pay or brand self-pay route.
Source: Point32Health provider notice · Confidence: confirmed · read October 15, 2026
CMS’s BALANCE model page says the Medicare GLP-1 Bridge ($50 copay for eligible Part D enrollees, which began July 1, 2026) is extended through December 31, 2027, and that BALANCE will not launch in Medicare in 2027.
What it means for cash-pay patients: Eligible Medicare Part D enrollees can keep the $50 copay through 2027; Medicare open enrollment runs October 15 to December 7.
Source: CMS · Confidence: confirmed · read October 15, 2026
FDA announced charges against two people accused of distributing counterfeit Ozempic sourced from China between 2023 and 2024. An indictment is an allegation only.
What it means for cash-pay patients: Buy brand GLP-1s only from licensed pharmacies, LillyDirect or NovoCare.
Source: U.S. FDA · Confidence: confirmed · read October 15, 2026
Warning letters 737806 (dated September 23) and 737810 (dated September 24), posted October 6, went to websites selling "Semanat" and "Semanext" injectable semaglutide as unapproved, misbranded drugs.
What it means for cash-pay patients: "Generic semaglutide" sold online is not a legitimate low-cost option.
Source: U.S. FDA (737806) · U.S. FDA (737810) · Confidence: confirmed · read October 15, 2026
At its Capital Markets Day, Novo Nordisk described U.S. self-pay and direct-to-patient sales as central to Wegovy, including the Wegovy pill.
What it means for cash-pay patients: Manufacturer-direct prices (Wegovy pill from $149) are now the benchmark for any compounded price.
Source: Novo Nordisk Capital Markets Day 2026 (US operations presentation) · Confidence: confirmed · read October 15, 2026
FDA’s letter, dated September 18 and posted September 22, says Empower’s tirzepatide-niacinamide and semaglutide-cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products", calls the claimed differences pretextual, and cites insanitary conditions in sterile production.
What it means for cash-pay patients: GLP-1 "plus vitamin" blends are not a safe harbour. Ask your program which pharmacy fills your prescription and whether it has changed.
Source: U.S. FDA · Confidence: confirmed · read October 15, 2026
Warning letters dated August 24 went to Peptide Partners (735063), Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652) and Tex Peptides (735067). FDA called their tirzepatide, semaglutide, retatrutide, tesamorelin, SS-31 and PT-141 products unapproved new drugs and said the "research use only" labels did not change that.
What it means for cash-pay patients: A research-use disclaimer does not make a peptide legal or safe to inject.
Source: U.S. FDA (734884) · U.S. FDA (735063) · Confidence: confirmed · read October 15, 2026
Louisiana SB 253, signed as Act 374, took effect August 1, 2026. Secondary summaries say it stops state licensing boards from disciplining prescribers who provide peptides from compliant 503A pharmacies or FDA-registered 503B outsourcers.
What it means for cash-pay patients: It protects Louisiana clinicians from state-board action; it does not change federal compounding status.
Source: Louisiana State Legislature · Confidence: confirmed (status); reported (content) · read October 15, 2026
The Pharmacy Compounding Advisory Committee met July 23–24 on BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500 to the 503A bulks list. A law-firm account reports the committee voted to recommend six of the seven (BPC-157, KPV and TB-500 each 8–6) and voted against DSIP.
What it means for cash-pay patients: A committee vote is advice. As of October 15, none of these peptides has been added to the bulks list.
Source: U.S. FDA (meeting page) · McDermott Will & Schulte (vote counts) · Confidence: confirmed (meeting); reported (votes) · read October 15, 2026
Prices behind these items: GLP-1 pricing database. Legal background: is compounded GLP-1 legal? and peptide legality.
| Date | What happened | Why it matters |
|---|---|---|
| March 2022 | Semaglutide (Wegovy) added to the FDA drug shortage list. | Shortage begins — the legal window for compounding opens. |
| August 2022 | Ozempic (semaglutide) added to the shortage list. | |
| December 15, 2022 | Tirzepatide (Mounjaro, Zepbound) added to the shortage list. | Compounded tirzepatide becomes lawful under the shortage exception. |
| October 2, 2024 | FDA declares the tirzepatide shortage resolved. | The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close. |
| December 19, 2024 | FDA reaffirms the tirzepatide resolution in a declaratory order. | Sets a 60-day (503A) / 90-day (503B) transition. |
| February 18, 2025 | 503A enforcement discretion for tirzepatide ENDS. | State-licensed pharmacies must stop compounding tirzepatide copies. |
| February 21, 2025 | FDA removes semaglutide from the shortage list. | |
| March 19, 2025 | 503B enforcement discretion for tirzepatide ENDS. | Outsourcing facilities must stop compounding tirzepatide copies. |
| April 22, 2025 | 503A enforcement discretion for semaglutide ENDS. | |
| April 24, 2025 | Court denies the Outsourcing Facilities Association's injunction (semaglutide). | OFA v. FDA, N.D. Tex. — FDA's determination stands. |
| May 7, 2025 | Court upholds FDA on tirzepatide in OFA v. FDA. | The shortage-exception route is closed for both molecules. |
| May 22, 2025 | 503B enforcement discretion for semaglutide ENDS. | All shortage-based compounding of both molecules is now outside enforcement discretion. |
| April 30, 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. | Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period extended to July 30, 2026 (91 FR 38719); no final decision as of October 15, 2026. |
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.
With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.
Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.
New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).